Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 7/20 | 0.46 |
| ▸ | CTSD | P07339 | 1/20 | 0.42 |
| ▸ | CHRND | Q07001 | 5/20 | 0.42 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.42 |
| ▸ | CHRNG | P07510 | 1/20 | 0.42 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | PLG | P00747 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.40 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.40 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23425699 | 0.94 | GRIA1 (0.45) | GRIA1CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL19682984 | 0.94 | GRIA1 (0.45) | GRIA1CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL19683054 | 0.87 | GRIA1 (0.49) | GRIA1CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL23425701 | 0.86 | CTSD (0.37) | GRIA1CTSDITGB3ITGA2B | |
| SCHEMBL23425637 | 0.85 | GRIA1 (0.46) | GRIA1CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL19683185 | 0.84 | ITGB3 (0.37) | GRIA1CTSDITGB3ITGA2B | |
| SCHEMBL19683216 | 0.84 | GRIA1 (0.49) | GRIA1CHRNDCHRNA1CHRNGCHRNB1 | |
| SCHEMBL24276205 | 0.84 | CTSD (0.37) | GRIA1CTSDITGB3ITGA2B | |
| SCHEMBL29360860 | 0.82 | GRIA1 (0.66) | GRIA1CHRNDCHRNA1CHRNGCHRNB1 | |
| Fosgonimeton SCHEMBL23425642 | 0.82 | SRC (0.51) | GRIA1CHRNDCHRNA1CHRNGCHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464336-B1 | COMPOUNDS | ATHIRA PHARMA INC (US) | 2022-03-16 | — | — | EP | disclosed |
| US-20210340176-A1 | Compounds | ATHIRA PHARMA, INC. (US) | 2021-11-04 | — | — | US | disclosed |
| US-11021514-B2 | Compounds | ATHIRA PHARMA, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| WO-2017210489-A1 | COMPOUNDS | M3 BIOTECHNOLOGY, INC. (US) | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021514-B2 | Compounds | BACE1, BDNF, CLN6 | GRIA1 1185/4885CTSD 403/4885CHRND 4159/4885 |
| US-20210340176-A1 | Compounds | BACE1, BDNF, CLN6 | GRIA1 1185/4885CTSD 403/4885CHRND 4159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.